US based AI clinical intelligence company Cohere Health has launched a Global Capability Centre in Hyderabad, marking its formal entry into India as it expands engineering, product and operations capabilities. The move reflects a broader trend of healthcare technology firms leveraging India’s talent ecosystem to scale artificial intelligence driven solutions for global markets.
Cohere Health focuses on applying AI to streamline prior authorisation and utilisation management processes in the US healthcare system. Its platform is designed to help health plans and providers automate clinical reviews, reduce administrative burdens and accelerate patient access to care. By establishing a GCC in Hyderabad, the company aims to deepen its technical expertise and enhance product innovation.
The Hyderabad centre will support engineering, data science, product development and operations functions. The company has indicated that the new facility will play a strategic role in building and refining its AI models, while also strengthening customer support and delivery capabilities. Hiring is expected across technology and healthcare domain roles, contributing to the city’s growing profile as a global AI and healthtech hub.
India has emerged as a preferred destination for Global Capability Centres, particularly in sectors such as financial services, healthcare and enterprise technology. Cities like Hyderabad, Bengaluru and Pune have attracted multinational firms seeking access to skilled engineers, data scientists and domain specialists. Industry estimates suggest that India hosts more than 1,500 GCCs, with a steady pipeline of new entrants each year.
Cohere Health’s expansion aligns with this broader GCC momentum. For healthcare focused AI companies, India offers a combination of technical talent, cost efficiencies and experience in managing large scale digital operations. Hyderabad in particular has developed a strong life sciences and pharmaceuticals ecosystem, supported by established IT infrastructure and state government initiatives.
The company’s AI platform uses machine learning and clinical intelligence to assess medical necessity and recommend evidence based care pathways. Prior authorisation remains a complex and time consuming process in the US healthcare system, often requiring manual review of clinical documentation. By automating aspects of this workflow, AI solutions aim to reduce delays and administrative overhead.
Healthcare payers have been increasingly investing in AI driven tools to manage costs while maintaining quality standards. Automation of utilisation management processes can improve consistency and transparency in decision making. However, industry observers emphasise the need for robust governance and oversight to ensure that AI systems align with regulatory requirements and patient safety standards.
The Hyderabad GCC is expected to contribute to product localisation, model training and performance optimisation. Building AI systems for healthcare requires access to large datasets and domain expertise to interpret clinical guidelines accurately. The Indian team will likely collaborate closely with US based stakeholders to ensure alignment with market specific needs.
The launch also reflects the globalisation of healthcare technology development. While patient facing services may be delivered in specific geographies, the underlying software and analytics capabilities are increasingly distributed across international teams. GCCs allow companies to operate in a follow the sun model, enabling continuous development cycles.
For India’s AI ecosystem, the entry of a specialised clinical intelligence firm adds depth to the healthtech segment. Domestic startups and multinational corporations alike are investing in AI applications across diagnostics, drug discovery, telemedicine and hospital management. The addition of prior authorisation automation broadens the spectrum of use cases anchored in the country.
Industry analysts note that healthcare AI remains a high growth sector, driven by rising data volumes, regulatory complexity and demand for operational efficiency. As health systems worldwide face cost pressures, automation and predictive analytics are being positioned as tools to improve outcomes while containing expenditure.
Cohere Health’s GCC launch comes at a time when global companies are reassessing supply chains and operational resilience. Establishing technology centres in India offers both diversification and scalability. The country’s expanding digital infrastructure and favourable policy environment have strengthened its appeal as a strategic location for innovation hubs.
The Hyderabad centre is expected to scale gradually, with phased hiring and capacity expansion. As the team grows, it may also support research into emerging AI techniques, including advanced natural language processing and predictive modelling tailored to clinical contexts.
For marketers and enterprise technology stakeholders, the development highlights the convergence of AI, healthcare and global talent strategies. GCCs are no longer limited to back office functions but are increasingly positioned as innovation engines. Companies are leveraging these centres to drive core product development and competitive differentiation.
Cohere Health’s decision to establish operations in Hyderabad underscores confidence in India’s role in the global AI landscape. As healthcare systems continue to digitise, cross border collaboration will be central to delivering scalable and compliant solutions.
The launch of the AI clinical intelligence GCC signals both geographic expansion for Cohere Health and continued growth for India’s technology services ecosystem. With AI adoption accelerating across sectors, specialised healthcare applications are expected to remain a key focus area for investment and innovation in the years ahead.